

26 October 2011 **RAC/A/18/2011** 

## Final Agenda

# 18<sup>th</sup> meeting of the Committee for Risk Assessment

26 – 28 October 2011 Helsinki, Finland

26 October: starts at 9:00 28 October: ends at 14:00

## Item 1 – Welcome & Apologies

#### Item 2 - Adoption of the Agenda

RAC/A/18/2011 Rev. 1

For adoption

## Item 3 – Declarations of conflicts of interest to the Agenda

## Item 4 – Adoption of the minutes of the RAC-17

RAC/M/17/2011

For adoption

## Item 5 – Administrative issues and information items

- 5.1 Status report on the RAC-17 action points
- **5.2** Outcome of written procedures
- 5.3 Report from other ECHA bodies and activities
  - Report on MB policy of handling of conflict of interest

RAC/18/2011/28 For information

## Item 6 – Requests under Article 77 (3)(c)

#### 6.1 Gallium arsenide

## For discussion and possible adoption

## Item 7 – CLH

#### 7.1 CLH Dossiers for discussion and possible adoption

- a. N-ethyl-2-pyrrolidone (NEP)
- b. Ammoniumpentadecafluorooctanoate (APFO)
- c. Perfluorooctanic acid (PFOA) and its salts
- d. Sulcotrione
- e. Nitrobenzene
- f. Penconazole
- g. Ethylbenzene
- h. Octadecylamine
- i. (Z)-octadec-9-enylamine
- j. Amines, hydrogenated tallow alkyl
- k. Amines, coco alkyl
- l. Amines, Tallow alkyl

#### 7.2 CLH Dossiers for first discussion

- m. Aluminium phosphide
- n. Trimagnesium diphosphide

## 7.3 Appointment of RAC (co-) rapporteurs for CLH dossiers

a. Appointment of RAC (co-) rapporteurs for CLH dossiers

RAC/18/2011/29 room document For agreement

#### 7.4 General CLH issues

a. State of play of the submitted CLH dossiers

RAC/18/2011/26

For information

b. Review of the process for developing CLH opinions

RAC/18/2011/33

room document For information

#### Item 8 – Restrictions

#### 8.1 Restriction Annex XV dossiers

a. Update on the Phthalates dossier

For information

#### 8.2 General restriction issues (if relevant)

a. Update on intended restriction dossiers

For information

8.3 Appointment of RAC (co-) rapporteurs for restrictions dossiers

RAC/18/2011/30 room document For agreement

#### Item 9 – Authorisation

9.1 Appointment of RAC rapporteurs for substances listed in Annex XIV (if relevant)

RAC/18/2011/31

room document For agreement

9.2 General authorisation issues (if relevant)

#### Item 10 – Guidance issues

- 10.1 Feedback from guidance consultations
- 10.2 Report on other guidance activities

RAC/18/2011/27

For information

#### Item 11 - Update on stakeholder participation in the work of RAC

#### (Closed Session)

RAC/18/2011/32 room document For agreement

#### Item 12 – Any other business

#### Item 13 - Main conclusions and Action Points of RAC-18

Table with main conclusions and action points from RAC-18

For adoption

000

#### PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-18

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

Some discussions may require a closed session

#### Wednesday, 26 October: Morning Session

- Item 1 Welcome & Apologies
- Item 2 Adoption of the Agenda
- Item 3 Declarations of conflicts of interest to the Agenda
- Item 4 Adoption of the minutes of the RAC-17
- Item 5 Administrative issues and information items
  - 5.1 Status report on the RAC-17 action points
  - 5.2 Outcome of written procedures
  - 5.3 Report from other ECHA bodies and activities
    - Report on MB policy of handling of conflict of interest

#### Item 8 – Restrictions

- 8.1 Restriction Annex XV dossiers
  - a. Update on the Phthalates dossier (short presentation by rapporteurs)
- 8.2 General restriction issues (*if relevant*)
  - b. Update on intended restriction dossiers
- Item 9 Authorisation
  - 9.2 General authorisation issues (*if relevant*)
- Item 11 Update on stakeholder participation in the work of RAC (Closed Session)

#### Item 7 – CLH

- 7.1 CLH Dossiers for discussion and possible adoption
  - h. Octadecylamine
  - i. (Z)-octadec-9-enylamine
  - j. Amines, hydrogenated tallow alkyl
  - k. Amines, coco alkyl
  - l. Amines, Tallow alkyl

#### Wednesday, 26 October: Afternoon Session

Item 7 – CLH

- 7.1 CLH Dossiers for discussion and possible adoption
  - g. Ethylbenzene
  - f. Penconazole
- 7.2 CLH Dossiers for first discussion
  - m. Aluminium phosphide
  - n. Trimagnesium diphosphide
- 7.1 CLH Dossiers for discussion and possible adoption
  - a. N-ethyl-2-pyrrolidone (NEP)
  - b. Ammoniumpentadecafluorooctanoate (APFO)
  - c. Perfluorooctanic acid (PFOA) and its salts
- Optional 7.1 CLH Dossiers for discussion and possible adoption: second discussion on CLH dossiers for adoption as needed.

#### **Thursday 27 October: Morning Session**

Item 7 – CLH

- 7.1 CLH Dossiers for discussion and possible adoption (cont.)
  - d. Sulcotrione
  - e. Nitrobenzene
- Item 6 Requests under Article 77 (3)(c)
  - 6.1 Gallium arsenide
- Optional 7.1 CLH Dossiers for discussion and possible adoption: continuation of discussion on CLH dossiers for adoption as needed.
- Optional 7.2 CLH Dossiers for discussion: continuation of discussion on CLH dossiers as needed.

#### **Thursday 27 October: Afternoon Session**

- Optional Item 6 Requests under Article 77 (3)(c) continuation of discussion if needed
  - 6.1 Gallium arsenide
- Optional 7.1 CLH Dossiers for discussion and possible adoption: continuation of discussion on CLH dossiers for adoption as needed.
- Optional 7.2 CLH Dossiers for discussion: continuation of discussion on CLH as needed.

#### **Friday 28 September: Morning Session**

Item 7 – CLH

- 7.4 General CLH issues
  - a. State of play of the submitted CLH dossiers

- b. Review of the process for developing CLH opinions
- Optional 7.1 CLH Dossiers for discussion and possible adoption: continuation of discussion on CLH dossiers for adoption as needed.
- 7.3 Appointment of RAC (co-) rapporteurs for CLH dossiers
- Item 8 Restrictions
  - 8.3 Appointment of RAC (co-) rapporteurs for restrictions dossiers
- Item 9 Authorisation
  - 9.1 Appointment of RAC rapporteurs for substances listed in Annex XIV (if relevant)
- Optional Item 6 Requests under Article 77 (3)(c): continuation of the discussion if needed
  - 6.1 Gallium arsenide
- Item 13 Main conclusions and Action Points of RAC-18
- Item 10 Guidance issues
  - 10.1 Feedback from guidance consultations
  - 10.2 Report on other guidance activities
- Item 12 Any other business